Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 10;17:29. doi: 10.1186/s12969-019-0333-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Changes in anterior chamber cell grade (a) and prednisolone dose (b) in Case 1. Anterior chamber cell grading in the right eye was 3+ (based on the Standardization of Uveitis Nomenclature Working Group classification) at presentation. After prednisolone 15 mg/day was initiated, ocular inflammation and best-corrected visual acuity (BCVA) gradually improved; however, relapse occurred in both eyes during tapering of prednisolone. Adalimumab was administered to avoid the side effects of systemic corticosteroid. BCVA improved to 1.5 in both eyes and the anterior chamber cell grade improved to less than 0.5+ within 2 weeks. Both local and systemic corticosteroid were discontinued, and complete control of inflammation was achieved with adalimumab